Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
68 hedge funds and large institutions have $52.9M invested in Regulus Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 23 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
5.63% less ownership
Funds ownership: 50.06% → 44.43% (-5.6%)
18% less funds holding
Funds holding: 83 → 68 (-15)
65% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 23
70% less capital inflows, than outflows
Capital inflows: $4.02M | Capital outflows: $13.4M
83% less call options, than puts
Call options by funds: $52K | Put options by funds: $301K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$894K |
| 2 |
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$653K |
| 3 |
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$455K |
| 4 |
Morgan Stanley
New York
|
+$258K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.78M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
-$1.51M |
| 3 |
DAFNA Capital Management
Los Angeles,
California
|
-$1.39M |
| 4 |
Numeric Investors
Boston,
Massachusetts
|
-$1.08M |
| 5 |
Abingworth
London,
United Kingdom
|
-$1.08M |
RGLS Hedge Fund Activity: Q4 2016 in Review
68 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2016, worth a combined $52.9M — down 39% from $87.4M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RGLS and 8 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 25 added.
The largest buyer was Millennium Management, adding an estimated $894K. The largest seller was Vanguard Group, cutting an estimated $1.78M.
- 68 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2016, down from 83 in Q3 2016.
- Funds reported $52.9M of Regulus Therapeutics stock for Q4 2016, down 39% quarter-over-quarter.
- 8 funds opened new Regulus Therapeutics positions in Q4 2016 and 23 closed out, a net change of -15 holders.
- The largest Regulus Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $894K added.
- The largest Regulus Therapeutics seller in Q4 2016 was Vanguard Group, an estimated $1.78M sold.
Based on aggregated 13F filings for Q4 2016.